avelumab plus SoC (n=63) vs. Standard of Care (SoC) (n=62)
randomized controlled trial
avelumab SoC
avelumab 10 mg/kg intravenously) added to carboplatin and paclitaxel (experimental group) every 3 weeks and then every 2 weeks as a single maintenance treatment after the end of chemotherapy
Standard of care
carboplatin AUC 5 and paclitaxel 175 mg/m² every 3 weeks for six to eight cycles